Drug intelligence / Profile preview

DNB-104

Development stage: Preclinical
Lead developer: De Novo Biotherapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Oral

Overview

DNB-104 is an mRNA-based bispecific natural killer (NK) cell engager being developed by De Novo Biotherapeutics for the treatment of acute lymphocytic leukemia (ALL). The therapeutic utilizes mRNA technology to encode a bispecific antibody designed to bridge NK cells and leukemic cells, thereby inducing targeted cytotoxicity. While the specific antigens targeted by the bispecific construct are currently undisclosed, the approach aims to harness the innate immune system's potent anti-tumor activity. The program is currently in the research stage of development.

Beyond the preview

Go deeper on DNB-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNB-104.

Explore the full profile